AstraZeneca's mRNA deal with China's CanSino comes a year after the British pharma ended a cardiovascular and oncology collaboration with Moderna.

Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two that AstraZeneca dumped last year.. The Big ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.

CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the ...

AstraZeneca said on Wednesday a review of real-world data showed its COVID-19 vaccine provided equally effective protection against hospitalisation and death after two doses as with current mRNA ...

At the recent ESCMID meeting, Astrazeneca plc presented a new mRNA vaccine against the SARS-CoV-2 virus that encodes for self-assembling virus-like particle (VLP) antigens. There is still a need for ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.